N@N

WESTBOROUGH, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Companyas President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 11^th Annual BIO Investor Forum on Wednesday, October 10, 2012 at 2:00 PM PDT. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXias sd-rxRNA technology platform.

Hosted by the Biotechnology Industry Organization (BIO), the 11TH Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 9-10 at the Palace Hotel in San Francisco, California.

The presentation will be webcast and available on the Company's website at [ http://www.rxipharma.com/investors/events/ ]

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or aRNAi,a have great promise because of their ability to asilence,a or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXias first RNAi product candidate, RXI-109, which targets CTGF (connective tissue growth factor), entered into a human clinical trial in June 2012 to evaluate its safety, tolerability and potential efficacy for scar prevention. For more information, please visit [ www.rxipharma.com ].

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceuticals Corporationas products and technologies.These forward-looking statements about future expectations, plans and prospects of the development of RXias products and technologies involve significant risks, uncertainties and assumptions, including the risk that RXi may not be able to successfully develop its candidates, the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products.Actual results may differ materially from those contemplated by these forward-looking statements.RXi does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.